Background: Thrombosis is an outcome of COVID-19 illness and has prognostic implications. There is no evidence that pregnant women fare worse from SARS-CoV-2 infection than do nonpregnant women of the same age, however there is evidence that pregnant women infected with COVID-19 do worse. Patients with severe COVID19 infection had a better prognosis when treated with anticoagulant therapy with LMWH which is considered the best option for preventive anticoagulation in COVID-19 illness .

Objectives: To measure the association between early vs. late initiation of anticoagulant therapy and the need for maternal respiratory support in pregnant women infected with Covid-19.

Subject and Methods: This study had been carried out at Obstetrics and Gynecology department, Masr El-Gededa military hospital on 100 pregnant women with confirmed Covid-19 infection

Results: Group B had much lower O2 saturation than Group A. Comparing groups A and B, there was a decline in Hb, WBCs, platelets, neutrophils, and lymphocytes in group B. Group B had considerably higher levels of serum creatinine and urea nitrogen than Group A. Group B had greater values for PT, INR, D- dimer, fibrinogen, LDH, CRP, ferritin, parity, and gestational age at infection compared to group A. In terms of breathing, pregnancy, and giving birth, there was a huge discrepancy between the two groups. The majority of patients required immediate CS due to emergencies.

Conclusion: Anticoagulant treatment taken early in the course of a Covid-19 infection in a pregnant woman is superior and more effective, and minimizes the need for maternal respiratory support